Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AIkido Pharma SPEX

Healthcare Biotechnology
AIkido Pharma Inc is a United States-based biotechnology company. The company is engaged in the development of small-molecule anti-cancer therapeutics. The company's drug portfolio includes therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).

Recent & Breaking News (NDAQ:SPEX)

Spherix Announces the Closing of CBM BioPharma Transaction

PR Newswire December 10, 2019

Spherix Notes Additional Patent Coverage Granted

PR Newswire November 27, 2019

Spherix Issues Update to Shareholders

PR Newswire October 21, 2019

Spherix Highlights ValuEngine Upgrade to 'Buy' Rating

PR Newswire October 17, 2019

Emerging Markets Report: In the Money

GlobeNewswire October 16, 2019

Spherix Sets Record Date for Dividend Distribution

PR Newswire October 11, 2019

Emerging Markets Report: Botox, Anthrax, and the Healing Power of Poison

GlobeNewswire October 2, 2019

Spherix Issues Update to Shareholders

PR Newswire October 1, 2019

Spherix Issues Update to Shareholders Regarding Planned Dividend Distribution

PR Newswire September 25, 2019

University of Maryland, Baltimore Grants Spherix Exclusive Option to License Anthrax Based Ovarian Cancer Drug PrAg-PAS

PR Newswire September 17, 2019

Spherix is Granted Exclusive Option to License Anticancer Drug from the University of Kentucky

PR Newswire September 11, 2019

Spherix Announces Results of Special Meeting of Shareholders

PR Newswire September 9, 2019

Spherix Urges Shareholders to Approve Purchase of CBM BioPharma, Inc. Assets at Special Meeting

PR Newswire August 19, 2019

United States Patent & Trademark Office Allows Patent Claims for CBM BioPharma, Inc.'s Patent Application for Pancreatic Cancer Treatment

PR Newswire June 26, 2019

Spherix Files Preliminary Proxy Statement Advancing the Planned Acquisition of Assets of CBM BioPharma, Inc.

PR Newswire June 19, 2019

Spherix Inc. (NasdaqCM: SPEX) Trading Below Book Value; Diversified Asset Base Adds Value

Accesswire June 11, 2019

StockLab Reports: By the Numbers

Accesswire June 6, 2019

SmallCap Sentinel: One-on-One with Spherix CEO, Anthony Hayes

Accesswire April 10, 2019

Emerging Markets Report: By Any Measure

Accesswire April 3, 2019

Spherix Issues Letter to Shareholders

PR Newswire April 2, 2019